|
1
|
Ryan BM, Robles AI and Harris CC: Genetic
variation in microRNA networks: the implications for cancer
research. Nat Rev Cancer. 10:389–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kasinski AL and Slack FJ: MicroRNAs en
route to the clinic: progress in validating and targeting microRNAs
for cancer therapy. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Edwards JK, Pasqualini R, Arap W and Calin
GA: MicroRNAs and ultraconserved genes as diagnostic markers and
therapeutic targets in cancer and cardiovascular diseases. J
Cardiovasc Transl Res. 3:271–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tryndyak VP, Beland FA and Pogribny IP:
E-cadherin transcriptional down-regulation by epigenetic and
microRNA-200 family alterations is related to mesenchymal and
drug-resistant phenotypes in human breast cancer cells. Int J
Cancer. 126:2575–2583. 2009.PubMed/NCBI
|
|
5
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hurteau GJ, Carlson JA, Roos E and Brock
GJ: Stable expression of miR-200c alone is sufficient to regulate
TCF8 (ZEB1) and restore E-cadherin expression. Cell Cycle.
8:2064–2069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hugo H, Ackland ML, Blick T, et al:
Epithelial-mesenchymal and mesenchymal-epithelial transitions in
carcinoma progression. J Cell Physiol. 213:374–383. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee TK, Poon RT, Yuen AP, et al: Twist
overexpression correlates with hepatocellular carcinoma metastasis
through induction of epithelial-mesenchymal transition. Clin Cancer
Res. 12:5369–5376. 2006. View Article : Google Scholar
|
|
10
|
Miki H, Uehara N, Kimura A, et al:
Resveratrol induces apoptosis via ROS-triggered autophagy in human
colon cancer cells. Int J Oncol. 40:1020–1028. 2012.PubMed/NCBI
|
|
11
|
Sheths S, Jajoo S, Kaur T, et al:
Resveratrolreducesprostate cancer growth and metastasis by
inhibiting the Akt/microRNA-21 pathway. PLoS One. 7:e516552012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin HT, Tian QZ, Guan L, Zhou Y, Huang XE
and Zhang H: In vitro and in vivo evaluation of the antitumor
efficiency of resveratrol against lung cancer. Asian Pac J Cancer
Prev. 14:1703–1706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jan CH, Friedman RC, Ruby JG and Bartel
DP: Formation, regulation and evolution of Caenorhabditis
elegans 3′UTRs. Nature. 469:97–101. 2011. View Article : Google Scholar
|
|
15
|
Tang H, Deng M, Tang Y, et al: miR-200b
and miR-200c as prognostic factors and mediators of gastric cancer
cell progression. Clin Cancer Res. 19:5602–5612. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ceppi P, Mudduluru G, Kumarswamy R, et al:
Loss of miR-200c expression induces an aggressive, invasive, and
chemoresistant phenotype in non-small cell lung cancer. Mol Cancer
Res. 8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Furumoto K, Arii S, Mori A, et al: RECK
gene expression in hepatocellular carcinoma: correlation with
invasion-related clinicopathological factors and its clinical
significance. Reverse-inducing-cysteine-rich protein with Kazal
motifs. Hepatology. 33:189–195. 2001. View Article : Google Scholar
|
|
18
|
Span PN, Sweep CG, Manders P, et al:
Matrix metalloproteınase inhibitor reversion-inducing cysteine-rich
protein with Kazal motif a prognostic marker for good clinical
outcome in human breast carcinoma. Cancer. 97:2710–7215. 2003.
|
|
19
|
Masui T, Doi R, Koshiba T, et al: RECK
expression in pancreatic cancer: its correlation with lower
invasiveness and better prognosis. Clin Can Res. 9:1779–1784.
2003.PubMed/NCBI
|
|
20
|
Takeuchi T, Hisanaga M, Nagao M, et al:
The membrane-anchored matrix metalloproteí nase (MMP) regulator
RECK in combination with MMP-9 serves as an informative prognostic
indicator for colorectal cancer. Clin Cancer Res. 10:5572–5579.
2004.
|
|
21
|
Lei L, Huang Y and Gong W: Inhibition of
miR-92b suppresses nonsmall cell lung cancer cells growth and
motility by targeting RECK. Mol Cell Biochem. 387:171–176. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Tsai YH and Tseng SH: RECK
regulated endoplasmic reticulum stress response and enhanced
cisplatin-induced cell death in neuroblastoma cells. Surgery.
154:968–979. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moenner M, Pluquet O, Bouchecareilh M, et
al: Integrated endoplasmic reticulum stress responses in cancer.
Cancer Res. 67:10631–10634. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tamaki N, Hatano E, Taura K, et al: CHOP
deficiency attenuates cholestasis-induced liver fibrosis by
reduction of hepatocyte injury. Am J Physiol Gastrointest Liver
Physiol. 294:G498–G505. 2008. View Article : Google Scholar : PubMed/NCBI
|
